查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1146209

肝病診斷市場——增長、趨勢、COVID-19 的影響和預測 (2022-2027)

Liver Disease Diagnostics Market - Growth, Trends, and Forecasts (2022 - 2027)
出版日期: | 出版商: Mordor Intelligence | 英文 120 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在 2022 年至 2027 年的預測期內，肝病診斷市場的複合年增長率預計為 5.8%。

COVID-19 對非 COVID-19 疾病的診斷和治療產生了重大影響，因為所有資源都已轉移給 COVID-19 患者。由於禁閉限制和高傳染性疾病的可能性，預計對醫院和診所的訪問量減少也將對研究市場產生重大影響。然而，據報導，COVID-19 可能對肝病患者產生嚴重影響，表明對肝病診斷市場具有潛在的積極影響。例如，根據 2021 年 5 月發表的題為“COVID-19 對肝病進展的影響”的研究，嚴重 COVID-19 的風險與酒精性肝損傷和酒精性肝硬化顯著相關。而肝硬化與免疫功能障礙有關，這與 COVID-19 的不良預後有關。因此，COVID-19有望衝擊肝病診斷市場。

預計推動肝病診斷市場增長的主要因素是全球酒精消費量的增加和肝病的高患病率。例如，根據 2021 年 6 月發表的題為“全球慢性肝病流行病學”的研究，慢性肝病 (CLD) 是全球死亡和發病的主要原因之一，約有 15 億人受到影響。此外，根據同一來源，最常見的患病原因是非酒精性脂肪性肝病 (NAFLD) (59%)，其次是乙型肝炎 (29%)、丙型肝炎 (9%) 和酒精性肝病 (NAFLD) (59%). 疾病 (ALD) (2%).同樣，根據 2021 年 9 月發表的“乙型肝炎病毒血清學標誌物在醫護人員中的全球流行率”研究報告，“乙型肝炎病毒血清學標誌物在醫護人員中的全球流行率。肝炎是一個全球性的公共衛生問題，乙型肝炎病毒根據薈萃分析，乙肝病毒 (HBV) 感染每年影響約 20 億人並導致 100 萬人死亡。此外，根據同一消息來源，醫護人員 (HCW) 感染乙肝病毒的風險很高，因為他們的職業涉及接觸患者的血液。因此，由於肝病負擔沉重，預計對肝病診斷產品的需求將增加，預計將推動研究市場的增長。

此外，酒精攝入量增加和肥胖等肝病相關風險因素預計將進一步對市場產生積極影響，因為這些因素預計將推動對肝病診斷產品的需求。例如，根據 2021 年 12 月發表的題為“COVID-19 大流行期間飲酒量增加對酒精相關肝病的影響”的研究，在 COVID-19 大流行期間，酒精相關肝病的飲酒量增加。一項建模研究發現，在 COVID-19 大流行期間，酒精消費的短暫增加顯著增加了與 ALD 相關的長期發病率和死亡率，美國的酒精消費量增加了高達 25%。根據同一份文件，到 2040 年，消費量的增加將導致酒精性肝病死亡人數增加 8,000 人，肝衰竭病例增加 18,700 人，肝癌病例增加 1,000 人。對有效和先進診斷工具的需求預計將增長，因此可以進行該治療。因此，由於上述因素，肝病診斷市場有望在預測期內增長。然而，與肝病檢測相關的高成本預計將在預測期內抑制研究市場的增長。

主要市場趨勢

在預測期內，影像檢測細分市場將佔據較大份額

由於與用於診斷肝病的其他診斷技術相比，成像測試具有很高的特異性，因此預計該市場將出現顯著增長。超聲、放射性核素掃描、計算機斷層掃描（CT）、磁共振成像（MRI）、內窺鏡逆行胰膽管造影（ERCP）、經皮經肝膽管造影、肝臟外科膽管造影、這是膽囊和膽道的圖像處理方法。影像學檢查可幫助醫生準確地檢查肝臟並檢測肝臟的早期形態變化。成像測試被廣泛使用，因此有望在預測期內見證健康增長。例如，2022 年，美國國家醫學圖書館宣布梯度反射回波 (GRE) MRI 是檢測肝脂肪變性存在和嚴重程度的最準確成像方式。

此外，肝臟成像市場的主要參與者正在提高意識並促進各種肝病的早期診斷以及新產品的開發和發布，這些新產品有望進一步推動研究領域的增長。我們相互合作前進。例如，2022 年 6 月，Echosense 和Novo Nordisk將合作採用非酒精性脂肪性肝炎 (NASH) 的無創診斷測試，以提高對該疾病的認識以及早期診斷和管理的重要性。正在與兩家公司希望到 2025 年將晚期至嚴重 NASH 的診斷率提高一倍。因此，由於上述因素，肝病診斷市場的影像檢測板塊預計在預測期內將佔據較大份額。

預計在預測期內北美將佔據主要市場份額

北美地區預計將主導市場，原因包括肝病患病率高、飲酒量高以及先進和強大的醫療基礎設施的存在。例如，根據加拿大肝臟基金會2021年的報告，2020年，非酒精性脂肪肝是最常見的肝臟疾病，影響超過700萬人，而肝癌是加拿大增長最快的疾病，使其成為最致命的癌症。因此，由於疾病的早期發現推動了北美地區研究市場的增長，預計該地區對肝病診斷產品的需求很高。

在北美地區，由於肝病負擔高以及相關的風險因素（如大量飲酒和肥胖），預計美國將主導市場。例如，根據美國疾病控制與預防中心 2022 年 1 月的更新，該國約有 480 萬人被診斷患有肝病。此外，根據同一份數據，該國的酒精消費量也很高，是增加肝病負擔的主要因素之一，約25.1%的18歲及以上成年人的酒精消費量在1%左右。前一年。我有 5 天或更多男性大量飲酒，女性 4 天或更多。因此，我國肝病負擔有望逐年加重，有望對市場產生積極影響。此外，隨著公司在市場上推出新的高級測試，人們的健康意識不斷提高，預計將對所研究的市場產生進一步的積極影響。例如，2022 年 1 月，Siemens Healthmeyers 在美國推出了增強型肝纖維化 (ELF) 測試，這是一種從頭上市的 ELF 測試，用於評估非酒精性脂肪性肝炎 (NASH) 患者的疾病進展。這是最早的測試之一預後血液測試獲得批准。因此，由於上述因素，預計北美地區將佔據較大的市場份額，其中美國將是預測期內肝病診斷市場的主要市場。

競爭格局

由於多家公司在全球和區域開展業務，因此肝病診斷市場分散且競爭激烈。該行業的主要公司包括 Abbott Laboratories、F. Hoffmann-La Roche Ltd、Thermo Fisher Scientific Inc、Randox Laboratories Ltd、Boston Scientific Corporation、Laboratory Corporation of America Holdings、Siemens Healthcare GmbH、BioMerieux SA、Quest Diagnostics Incorporated、Biosino Bio -Technology and Science Inc 和 Echosens。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動因素
    • 飲酒量增加
    • 肝病患病率增加
  • 市場製約因素
    • 診斷測試成本高
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模：百萬美元）

  • 通過診斷技術
    • 肝活檢
    • 圖像檢查
    • 肝功能檢查
    • 內窺鏡檢查
  • 最終用戶
    • 醫院
    • 研究所
    • 其他最終用戶
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東和非洲
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章競爭格局

  • 公司簡介
    • Abbott
    • F. Hoffmann-La Roche Ltd.
    • Thermo Fisher Scientific Inc.
    • Randox Laboratories Ltd.
    • Boston Scientific Corporation
    • Laboratory Corporation of America Holdings
    • Siemens Healthcare GmbH
    • BioMerieux SA
    • Quest Diagnostics Incorporated
    • Biosino Bio-Technology and Science Inc

第七章市場機會與未來趨勢

簡介目錄
Product Code: 91559

The liver disease diagnostics market is expected to register a CAGR of 5.8% over the forecast period, 2022-2027.

COVID-19 had a significant impact on the diagnosis and treatment of diseases other than COVID-19 as all the resources were diverted for the COVID-19 patients and also, due to lockdown restrictions and high chances of contracting infection, the footfall in the hospitals and clinics reduced for diseases other than COVID-19 which was expected to have a significant impact on the studied market. However, it was reported that COVID-19 may have a severe impact on people with liver diseases which might have a positive impact on the liver disease diagnostics market. For instance, according to a research study published in May 2021, titled "Impact of COVID-19 in Liver Disease Progression", the risk of severe COVID-19 was significantly associated with alcoholic liver damage and alcoholic liver cirrhosis, and also, cirrhosis is associated with immune dysfunction, which is related to a bad COVID-19 prognosis. Hence, COVID-19 is anticipated to have an impact on the liver disease diagnostics market.

The major factors that are expected to fuel growth in the liver disease diagnostics market are the increasing consumption of the alcohol and high prevalence of liver diseases around the world. For instance, according to the research study published in June 2021, titled "Global Epidemiology of Chronic Liver Disease", chronic liver disease (CLD) is one of the leading causes of mortality and morbidity around the world and affects about 1.5 billion people across the world. Further, as per the same source, the most common causes of prevalent disease are non-alcoholic fatty liver disease (NAFLD) (59%), followed by hepatitis B (29%), hepatitis C (9%), and alcoholic liver disease (ALD) (2%). Similarly, according to a research study published in September 2021, titled "Global Prevalence of Hepatitis B Virus Serological Markers Among Healthcare Workers: A Systematic Review and Meta-Analysis", hepatitis is a global public health issue, and the hepatitis B virus (HBV) infection affects around 2 billion individuals and results in 1 million fatalities each year. Also, as per the same source, healthcare workers (HCWs) are at high risk for HBV because of the occupational risk to patient blood. Hence, due to the high burden of liver diseases, the demand for liver disease diagnostics products is expected to increase which is anticipated to drive growth in the studied market.

In addition, the increasing consumption of alcohol and an associated risk factor for liver disease like obesity is further expected to have a positive impact on the market as these factors are expected to boost the demand for liver disease diagnostics products. For instance, according to a research study published in December 2021, titled "Effect of Increased Alcohol Consumption During COVID-19 Pandemic on Alcohol-Associated Liver Disease: A Modeling Study", during the COVID-19 pandemic, a temporary rise in alcohol intake can significantly raise long-term ALD-related morbidity and mortality, and it was observed that the alcohol consumption increases up to 25% in the United States. Also, as per the same source, this increase in consumption can lead to 8,000 additional deaths from alcohol-related liver disease, 18,700 cases of liver failure, and 1,000 cases of liver cancer by 2040, which is expected to increase the demand for effective and advanced diagnostic tools so that appropriate medical attention can be provided to the patient. Therefore, due to the above-mentioned factors, the liver disease diagnostics market is expected to grow over the forecast period. However, high costs associated with liver disease tests are expected to restrain the growth of the studied market over the forecast period.

Key Market Trends

Imaging Tests Segment is Expected to Hold a Significant Share in the Market Over the forecast Period

The imaging segment is expected to have significant growth in the market due to its high specificity when compared with other diagnostic techniques used in liver disease diagnostics. Ultrasonography, radionuclide scanning, computed tomography (CT), magnetic resonance imaging (MRI), endoscopic retrograde cholangiopancreatography (ERCP), percutaneous transhepatic cholangiography, and surgical cholangiography are imaging procedures for the liver, gallbladder, and biliary tract. The imaging tests help doctors with an accurate examination of the liver enabling them to early detection of morphological changes in the liver the imaging tests are used widely and hence, are expected to have a healthy growth over the forecast period. For instance, in 2022, the National Library of Medicine of the United States published that gradient recalled echo (GRE) MRI is the most accurate imaging method to detect the existence and severity of hepatic steatosis.

Additionally, the key players in the market of liver imaging diagnostics are partnering with each other to increase awareness and advance the early diagnosis of various liver diseases along with the development and launch of new products which are further expected to boost growth in the studied segment. For instance, in June 2022, Echosens and Novo Nordisk collaborated on the adoption of non-invasive diagnostic tests for non-alcoholic steatohepatitis (NASH) and work together to increase awareness of the disease and the importance of early diagnosis and management. By 2025, the firms hope to have doubled the rate of diagnoses for those with advanced to severe NASH. Therefore, due to the above-mentioned factors, the imaging tests segment in the liver disease diagnostics market is expected to have a significant share over the forecast period.

North America Region is Expected Occupy Major Share in the Market Over the Forecast Period

North American region is expected to dominate the market due to factors such as the high prevalence of liver diseases, high-alcohol consumption, the presence of advanced and robust healthcare infrastructure, and other factors. For instance, according to the 2021 report of the Canadian Liver Foundation, in 2020, non-alcoholic fatty liver disease was the most common liver disease, affecting over 7 million people and liver cancer is the fastest rising and deadliest form of cancer in Canada. Thus, the demand for liver disease diagnostics products in the region is expected to be high for the early detection of the disease which will fuel growth in the studied market in the North America region.

In the North American region, the United States is expected to dominate the market owing to the high burden of liver diseases and associated risk factors such as high consumption of alcohol and obesity. For instance, according to the January 2022 update of the Centers for Disease Control and Prevention, about 4.8 million people in the country are living with diagnosed liver disease. Further, as per the same source, alcohol consumption is also very high in the country which is one of the major factors responsible for the increase in the burden of liver disease and about 25.1% of adults of age 18 and more had approximately one heavy drinking day (five or more drinks for men and four or more drinks for women) in the previous years. Hence, the burden of liver diseases in the country is expected to increase over the years which is anticipated to have a positive impact on the market. Moreover, the growing health awareness along with the launch of new and advanced tests by the companies in the market is further expected to have a positive impact on the studied market. For instance, in January 2022, Siemens Healthineers launched enhanced liver fibrosis (ELF) test in the United States and the ELF test is one of the first prognostic blood tests granted De Novo marketing authorization to assess disease progression in non-alcoholic steatohepatitis (NASH) patients. Therefore, owing to the above-mentioned factors, the North American region is expected to hold a significant market share, in which the United States will be a major market for the liver disease diagnostics market over the forecast period.

Competitive Landscape

The liver disease diagnostics market is fragmented in nature due to the presence of several companies operating globally as well as regionally and thus, it is moderately competitive. SOme of the key companies operating in the industry are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc, Randox Laboratories Ltd, Boston Scientific Corporation, Laboratory Corporation of America Holdings, Siemens Healthcare GmbH, BioMerieux SA, Quest Diagnostics Incorporated, Biosino Bio-Technology and Science Inc, and Echosens.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increase in Alcohol Consumption
    • 4.2.2 Increase in Prevalence of Liver Diseases
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Diagnostic Test
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Diagnosis Technique
    • 5.1.1 Liver Biopsy
    • 5.1.2 Imaging Tests
    • 5.1.3 Liver Function Tests
    • 5.1.4 Endoscopy
  • 5.2 By End User
    • 5.2.1 Hospitals
    • 5.2.2 Laboratories
    • 5.2.3 Other End Users
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott
    • 6.1.2 F. Hoffmann-La Roche Ltd.
    • 6.1.3 Thermo Fisher Scientific Inc.
    • 6.1.4 Randox Laboratories Ltd.
    • 6.1.5 Boston Scientific Corporation
    • 6.1.6 Laboratory Corporation of America Holdings
    • 6.1.7 Siemens Healthcare GmbH
    • 6.1.8 BioMerieux SA
    • 6.1.9 Quest Diagnostics Incorporated
    • 6.1.10 Biosino Bio-Technology and Science Inc

7 MARKET OPPORTUNITIES AND FUTURE TRENDS